新型冠狀病毒肺炎（COVID-19）來勢(shì)洶洶，而合并其他基礎(chǔ)疾病的COVID-19患者更屬于高危人群。血糖控制水平直接影響身體免疫應(yīng)答和狀態(tài)，其導(dǎo)致的免疫力低下狀態(tài)極易增加患病幾率，已感染的患者則更易加重感染，進(jìn)一步繼發(fā)細(xì)胞因子風(fēng)暴。因此COVID-19合并2型糖尿病患者在疫情期間需要在治療新型冠狀病毒感染的同時(shí)做好血糖控制和管理。結(jié)合糖尿病合理用藥相關(guān)研究，對(duì)COVID-19現(xiàn)有臨床數(shù)據(jù)特征進(jìn)行分析，探討COVID-19合并糖尿病患者的藥學(xué)實(shí)踐模式和用藥監(jiān)護(hù)策略，以期對(duì)這類患者提供更為優(yōu)化合理的用藥方案，改善臨床用藥水平。

New coronavirus pneumonia is menacing, and patients with new coronavirus pneumonia combined with other underlying diseases are more at risk. Glycemic control level directly affects the body's immune response and body state. Its low immune status is extremely likely to increase the risk of illness. Infected patients are more likely to aggravate the infection and further cause cytokine storms. Therefore, patients with new type of coronavirus infection and type 2 diabetes need better blood glucose control and management while treating new type of coronavirus infection. This article combines the research on the rational use of diabetes and analyzes the characteristics of the existing clinical data of COVID-19 to explore the pharmacological practice mode and medication monitoring strategy of this special patient. It is hoped to provide COVID-19 patients with diabetes with a more optimized and reasonable medication regimen and improve the clinical medication level.

R288.4

國(guó)家重點(diǎn)研發(fā)項(xiàng)目計(jì)劃精準(zhǔn)醫(yī)學(xué)研究重點(diǎn)項(xiàng)目（2017YFC0909904）